April 2018

New Product - Glyxambi

Glyxambi (empagliflozin/linagliptin) contains two oral antihyperglycaemic drugs used in the management of type 2 diabetes mellitus (T2DM): empagliflozin (a SGLT2 inhibitor) and linagliptin (a DPP-4 inhibitor). Empagliflozin and linagliptin act by separate and complementary mechanisms to treat T2DM. Glyxambi is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM when treatment with both empagliflozin and linagliptin is appropriate. Glyxambi is contraindicated with eGFR persistently < 45 mL/min/1.73 m² or CrCl persistently < 45 mL/min (CKD stage 3B), as the efficacy of empagliflozin is dependent on renal function. Glyxambi 10 mg/5 mg and 25 mg/5 mg tablets are available in packs of 30.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au